AI Stock Analysis - Illumina (ILMN)
Analysis generated November 17, 2025.
Illumina, Inc. is a leading company in the field of genomic sequencing. Known for innovation and a robust portfolio, Illumina provides a wide range of solutions that enable the analysis of genetic variation and function. These capabilities are critical for many areas of research, including cancer research, genetic disease diagnostics, and personalized medicine, positioning Illumina as a key player in the rapidly growing genomics market.
Stock Alerts - Illumina (ILMN)
 |
Illumina | February 12 Insider Alert: Gottlieb Scott is buying shares |
|
Illumina | February 10 Business Outlook among employees is up by 3.1% over the last month. |
|
Illumina | February 9 Over the past few months, there has been an downward trend in Web Traffic. |
|
Illumina | February 6 Price is down by -6.4% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Illumina
About Illumina
Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function.
| Price | $116.81 |
| Target Price | Sign up |
| Volume | 1,750,000 |
| Market Cap | $17.9B |
| Year Range | $84.98 - $153.95 |
| Dividend Yield | 0% |
| PE Ratio | 21.39 |
| Analyst Rating | 50% buy |
| Industry | Biotechnology |
In the news
 |
Illumina Q4 Earnings & Revenues Top Estimates, Stock DipsFebruary 11 - Yahoo |
|
Illumina's (NASDAQ:ILMN) Profits Appear To Have Quality IssuesFebruary 11 - Yahoo |
|
5 Insightful Analyst Questions From Illumina’s Q4 Earnings CallFebruary 11 - Yahoo |
|
Unlocking Illumina (ILMN) International Revenues: Trends, Surprises, and ProspectsFebruary 8 - Yahoo |
Piper Sandler Maintains Overweight on Illumina, Lowers Price Target to $170February 8 - Benzinga |
|
|
Is Illumina’s (ILMN) Clinical Consumables Surge Quietly Redefining Its Core Investment Story?February 7 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '25 | 1.16B | 382M | 777M | 334M | 445M | 1.350 |
| Q3 '25 | 1.08B | 351M | 732M | 150M | 337M | 1.340 |
| Q2 '25 | 1.06B | 364M | 695M | 235M | 399M | 1.190 |
| Q1 '25 | 1.04B | 358M | 683M | 131M | 276M | 0.970 |
| Q4 '24 | 1.1B | 376M | 728M | 187M | 283M | 0.860 |
Insider Transactions View All
| Gottlieb Scott filed to buy 12,723 shares at $117.8. February 11 '26 |
| Davies Scott M filed to sell 17,887 shares at $136.1. December 16 '25 |
| Wedel Christensen Jakob filed to sell 10,952 shares at $129.3. December 9 '25 |
| Gottlieb Scott filed to buy 12,523 shares at $122.1. November 5 '25 |
| Thaysen Jacob filed to buy 83,390 shares at $82.3. May 14 '25 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Lisa McClain |
Aug 13, 25 | Buy | $1K - $15K |
| Thomas H. Kean |
Apr 21, 25 | Buy | $1K - $15K |
| Rohit Khanna Democrat |
Jun 5, 24 | Buy | $1K - $15K |
Read more about Illumina (ILMN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
FAQ - Illumina
The Market Cap of Illumina is $17.9B.
As of today, Illumina's PE (Price to Earnings) ratio is 21.39.
Currently, the price of one share of Illumina stock is $116.81.
The ILMN stock price chart above provides a comprehensive visual representation of Illumina's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Illumina shares. Our platform offers an up-to-date ILMN stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Illumina (ILMN) does not offer dividends to its shareholders. Investors interested in Illumina should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Illumina are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
